CMS Hasche Sigle advises synlab on acquisition of laboratory group in Estonia, Finland and Lithuania

Hamburg, 1 August 2013 – Augsburg-based synlab Group, a leading lab service provider in Europe, has acquired 100% of Medicap Holding AS from private equity fund BaltCap and other shareholders. Medicap operates laboratories in Estonia, Finland and Lithuania under the trading names Quattromed and Sorpo. The acquisition means that the lab network now has a presence in 21 European countries, plus Turkiye, Saudi Arabia and Dubai. synlab is the first international lab chain to invest in the Baltic markets. The purchase price was not disclosed.

A team led by lead partner Dr Jacob Siebert advised synlab on all aspects of the transaction. CMS Hasche Sigle was supported by Finnish-Baltic law firm Borenius.

The synlab Group was formed at the end of 2009 through the merger of three lab chains in Germany, Austria and Italy, with CMS Hasche Sigle partner Dr Udo Simmat advising in the lead role. Since then it has grown both organically and through further acquisitions. Dr Udo Simmat has for many years been advising global private equity firm BC Partners, which is synlab’s majority shareholder. At the beginning of this year, synlab entered the Belgian market by acquiring the Laboratoire Dr. Collard group. This transaction was also supported by a team led by Dr Jacob Siebert, together with a team headed by Arnaud Van Oenkel from CMS's office in Brussels.

Medicap Holding includes Quattromed HTI in Estonia, Quattromed Finland and Sorpo in Lithuania. The three subsidiaries each have a strong market position among private medical labs in their respective countries. The lab alliance has more than 200 employees and carries out over five million tests a year for GPs, hospitals and private patients.

CMS Hasche Sigle

Dr Jacob Siebert, M&A, Private Equity, Lead Partner
Dr Udo Simmat, M&A, Private Equity
Dr Tobias Schneider, M&A, Private Equity
Dr Christoph Lächler, M&A, Due Diligence

Press Contact
presse@cms-hs.com